UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics Inc.’s stock declined 35% after the FDA announced manufacturing deficiencies at a third-party vendor, delaying a key treatment’s approval and raising concerns about the company’s future growth prospects.

Unicycive Therapeutics Inc. saw its stock price drop 35% after the FDA identified manufacturing deficiencies at a third-party vendor, delaying the approval of its key treatment for hyperphosphatemia.

Unicycive Therapeutics, Inc. is a biotech company developing innovative therapies to treat hyperphosphatemia, a common condition associated with chronic kidney disease and acute kidney injury.